Home › with Excess of Blasts Refractory Anemia › Washington
with Excess of Blasts Refractory Anemia clinical trials in Washington
5 studies for with Excess of Blasts Refractory Anemia are looking for participants at sites in Washington.
Cities in Washington
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Jun 22, 2026 · NCT03128034211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Jun 22, 2026 · NCT03670966A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Seattle Cancer Care Alliance, Seattle
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Apr 30, 2026 · NCT04256317A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 2
Ages 18 to 66 · All sexes · Updated Mar 17, 2026 · NCT06859424HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- Fred Hutchinson Cancer Research Center, Seattle
RecruitingPhase 2
3 Months · All sexes · Updated Nov 12, 2025 · NCT02143830From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.